Becton, Dickinson and Company Announces Quarterly Dividend of $1.05 (NYSE:BDX)

Becton, Dickinson and Company (NYSE:BDX) declared a quarterly dividend on Tuesday, January 27th. Shareholders of record on Tuesday, March 10th will be paid a dividend of 1.05 per share by the medical instruments supplier on Tuesday, March 31st. This represents a c) dividend on an annualized basis and a yield of 2.1%. The ex-dividend date of this dividend is Tuesday, March 10th.

Becton, Dickinson and Company has increased its dividend payment by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 53 consecutive years. Becton, Dickinson and Company has a dividend payout ratio of 28.5% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect Becton, Dickinson and Company to earn $15.64 per share next year, which means the company should continue to be able to cover its $4.20 annual dividend with an expected future payout ratio of 26.9%.

Becton, Dickinson and Company Stock Down 0.2%

Shares of NYSE BDX traded down $0.51 during trading on Wednesday, reaching $202.90. The company had a trading volume of 514,742 shares, compared to its average volume of 1,701,434. Becton, Dickinson and Company has a 12-month low of $162.29 and a 12-month high of $251.99. The company has a quick ratio of 0.64, a current ratio of 1.11 and a debt-to-equity ratio of 0.69. The business’s 50-day moving average is $197.87 and its 200 day moving average is $190.90. The stock has a market cap of $57.81 billion, a PE ratio of 34.81, a P/E/G ratio of 2.25 and a beta of 0.23.

Becton, Dickinson and Company (NYSE:BDX) last announced its quarterly earnings results on Thursday, November 6th. The medical instruments supplier reported $3.96 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.92 by $0.04. The company had revenue of $5.89 billion for the quarter, compared to analysts’ expectations of $5.91 billion. Becton, Dickinson and Company had a net margin of 7.68% and a return on equity of 16.42%. Becton, Dickinson and Company’s revenue was up 8.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted $3.81 EPS. Becton, Dickinson and Company has set its FY 2026 guidance at 14.750-15.050 EPS. As a group, equities analysts forecast that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

BDX has been the topic of several analyst reports. Morgan Stanley upped their price objective on Becton, Dickinson and Company from $197.00 to $210.00 and gave the company an “overweight” rating in a research report on Tuesday, December 2nd. Jefferies Financial Group lifted their price objective on Becton, Dickinson and Company from $215.00 to $220.00 and gave the stock a “buy” rating in a report on Wednesday, December 10th. Weiss Ratings restated a “hold (c-)” rating on shares of Becton, Dickinson and Company in a research note on Wednesday, October 8th. Piper Sandler lifted their price target on shares of Becton, Dickinson and Company from $190.00 to $205.00 and gave the stock a “neutral” rating in a research note on Wednesday. Finally, Bank of America boosted their price objective on shares of Becton, Dickinson and Company from $190.00 to $207.00 and gave the company a “neutral” rating in a report on Monday, January 5th. Four equities research analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $209.00.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company (BDX) is a global medical technology company that develops, manufactures and sells a broad range of medical devices, instrument systems and reagents. BD’s products are used by healthcare institutions, clinical laboratories, life science researchers and the pharmaceutical industry to enable safe, effective delivery of care, specimen collection and diagnostic testing. The company’s operations span multiple business areas focused on medical devices, life sciences research tools and interventional technologies.

BD’s product portfolio includes single-use medical devices such as syringes, needles, needlesafety and injection systems, infusion therapy and medication management solutions, as well as vascular access, urology and oncology devices acquired through its interventional business.